PharmaShots | Incisive News in 3 Shots

Subscribe Now

Interim

Merck to Acquire OncoImmune for $425M

Merck to Acquire OncoImmune for $425M

November 24, 2020

Lilly's Bamlanivimab (LY-CoV555) Receives Health Canada's Interim Authorization as a Treatment for COVID-19

Lilly's Bamlanivimab (LY-CoV555) Receives Health Canada's Interim Authorization as a Treatment for COVID-19

November 23, 2020

Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC

Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC

November 12, 2020

CureVac Publishes Results of CVnCoV in Interim P-l Study for COVID-19

CureVac Publishes Results of CVnCoV in Interim P-l Study for COVID-19

November 11, 2020

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of P-II GALAXI 1 Study for Moderately to Severely Active Crohn's Disease

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of P-II GALAXI 1 Study for Moderately to Severely Active Crohn...

October 12, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us